The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force

Noel Southall, Madhusudan Natarajan, Lilian Pek Lian Lau, Anneliene Hechtelt Jonker, Benoît Déprez, Tim Guilliams, Lawrence Hunter, Carin M. A. Rademaker, Virginie Hivert, Diego ArdigòOrphanet 2019 · DOI

TL;DR

This paper outlines recommendations from the IRDiRC Data Mining and Repurposing Task Force to accelerate the discovery of new treatments for rare diseases. It emphasizes strategic investments in data infrastructure, including better patient data capture, integration of research data, enhanced experimental testing, and shared expertise, to overcome the significant unmet medical need in this area.

What Problem Does This Paper Address?

The paper tackles the critical challenge of the low number of approved treatments for rare diseases, with fewer than 6% having an available therapy. This represents a vast unmet medical need, affecting over 350 million people worldwide, many of whom are children. The development of orphan drugs is fraught with difficulties, including limited understanding of disease epidemiology and progression, lack of consensus on clinical endpoints, and complex trial designs, all leading to time- and resource-intensive processes. The paper highlights that despite the growing capacity to generate biomedical data, its effective utilization for rare disease drug development, particularly through data mining and drug repurposing, is hindered by several infrastructural and strategic gaps.

Methods

The paper doesn't describe a single novel method or algorithm. Instead, it presents a set of recommendations derived from a multi-stakeholder task force. The "methods" here refer to the process of the task force: reviewing past successes in data mining for drug repurposing, examining current research capacity, and identifying strategic areas for investment. The task force's approach involved:

  • Review of existing literature and case studies: Analyzing successful instances of data mining and drug repurposing for rare diseases.
  • Expert consensus building: Bringing together researchers, industry professionals, and patient advocates to discuss challenges and opportunities.
  • Identification of key infrastructure investment areas: Pinpointing critical domains where improvements are needed to accelerate progress.
  • Development of strategic recommendations: Proposing actionable steps to enhance data mining and repurposing efforts.

The paper also discusses the application of existing data mining and computational modeling techniques, such as those used to predict compound-ligand interactions, perform high-throughput screening, and analyze molecular mechanisms.

Datasets

The paper does not introduce or evaluate specific datasets. Instead, it discusses the types of data that are crucial for rare disease research and drug development:

  • Self-reported patient data: Information gathered from patients through social media, health forums, and patient-centric research platforms.
  • Existing research data: Data from various academic and clinical research settings.
  • Real-world data: Including patient records and data on off-label drug use.

The paper emphasizes the need for better capture, sharing, and integration of these data types, rather than presenting results from specific datasets.

Key Insights and Ideas

  • Drug repurposing is a powerful strategy: Leveraging existing drugs for new indications offers a faster and potentially cheaper route to new treatments for rare diseases, capitalizing on reduced safety and pharmacokinetic risks.
  • Data is abundant but fragmented: While vast amounts of biomedical data are being generated, their scattered nature and lack of standardization hinder their effective use for rare disease research.
  • Infrastructure is key: Accelerating rare disease drug development requires strategic investments in four core areas: improving patient data capture and sharing, better integration of research data, increasing experimental testing capacity, and fostering the sharing of expertise.
  • Patient engagement is vital: Patients are increasingly involved in reporting their conditions and outcomes, and their data, when standardized and shared, can significantly support research and repurposing efforts.
  • Off-label use data is a goldmine: Capturing and analyzing data on the off-label use of medicines can uncover new therapeutic opportunities for rare diseases.
  • "Target in Disease" dashboards are needed: Creating integrated, curated disease maps that link pathways, indications, and research data can help identify knowledge gaps and prioritize research efforts.
  • FAIR principles are essential: Adherence to Findable, Accessible, Interoperable, and Reusable (FAIR) principles is crucial for effective data sharing and integration in rare disease research.
  • Linking rare and common diseases offers mutual benefits: Insights gained from studying rare diseases can inform the development of treatments for common diseases, and vice versa.

Key Results

This paper is a position statement and a set of recommendations, not an empirical study with quantitative results. Therefore, there are no specific numerical results to summarize. The "results" are the identified strategic areas and recommended strategies.

Limitations and Future Work

Limitations:

  • Funding challenges: The paper acknowledges that a sustainable funding model is needed to support the creation and maintenance of open-source databases and data infrastructure.
  • Intellectual property concerns: While intellectual property protection is seen as essential for attracting investment, it can also hinder data sharing and collaboration.
  • Data quality and standardization: Variable data standards, privacy concerns, and the potential for inaccurate reporting complicate the use of self-reported patient data.
  • Complexity of clinical trials: Despite repurposing, clinical trial design and organization for rare diseases remain challenging due to small patient populations.

Future Work:

  • Develop standardized data collection methods: Creating data standards in consultation with patients and clinicians, and validated by IT providers, is crucial.
  • Establish "Target in Disease" dashboards: Building integrated, curated disease maps to facilitate data mining and research prioritization.
  • Foster public-private partnerships: Encouraging collaboration between academic institutions, industry, and patient organizations.
  • Promote open-source data sharing: Advocating for Creative Commons or equivalent licensing to facilitate data integration and mining.
  • Enhance experimental testing capacity: Investing in the creation of cell and animal models to validate in silico findings.
  • Nurture rare disease research expertise: Developing educational programs and support systems for researchers in this specialized field.
  • Explore novel data mining and repurposing opportunities: Continuously developing and applying advanced analytical models.
  • Address market incentives: Ensuring that economic incentives are adequate to encourage drug repurposing, especially for drugs whose patents have expired.

Summary updated

Abstract

The number of available therapies for rare diseases remains low, as fewer than 6% of rare diseases have an approved treatment option. The International Rare Diseases Research Consortium (IRDiRC) set up the multi-stakeholder Data Mining and Repurposing (DMR) Task Force to examine the potential of applying biomedical data mining strategies to identify new opportunities to use existing pharmaceutical compounds in new ways and to accelerate the pace of drug development for rare disease patients. In reviewing past successes of data mining for drug repurposing, and planning for future biomedical research capacity, the DMR Task Force identified four strategic infrastructure investment areas to focus on in order to accelerate rare disease research productivity and drug development: (1) improving the capture and sharing of self-reported patient data, (2) better integration of existing research data, (3) increasing experimental testing capacity, and (4) sharing of rare disease research and development expertise. Additionally, the DMR Task Force also recommended a number of strategies to increase data mining and repurposing opportunities for rare diseases research as well as the development of individualized and precision medicine strategies.
BibTeX
@inproceedings{southall2019use,
  author = {Noel Southall and Madhusudan Natarajan and Lilian Pek Lian Lau and Anneliene Hechtelt Jonker and Benoît Déprez and Tim Guilliams and Lawrence Hunter and Carin M. A. Rademaker and Virginie Hivert and Diego Ardigò and Diego Ardigò},
  title = {{The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force}},
  booktitle = {Orphanet},
  year = {2019},
  doi = {10.1186/s13023-019-1193-3},
}
Figure